Database Locked and Finalized for Phase 3 Trial of MDMA-Assisted Therapy for PTSD (MAPP2)
December 21, 2022
Together, we have been on a 36-year journey to obtain FDA approval for the therapeutic use of MDMA and, thanks to donors and friends like you, we are celebrating more critical milestones this month!
In the most advanced psychedelic-assisted therapy development program, the MAPS PBC research team locked and finalized the database for our second Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (MAPP2) on November 22. Locking the database officially brought the data collection phase of the study to a close. Next, the MAPS PBC research team will analyze the evidence and write a paper for submission to a peer-reviewed scientific journal.
The final participant in this study completed their final session on November 2, 2022. With these two steps, the U.S. Food and Drug Administration (FDA)’s evaluation of the treatment’s safety and efficacy is expected to take place in 2023.
Thank You to Bryce Montgomery for 11 Years of Dedication to MAPS
In a bittersweet moment, we celebrate the significant contributions of long-term staff member Bryce Montgomery, Associate Director of Marketing Communications, who is moving on to a new chapter.
Since 2011, Bryce has developed an encyclopedic knowledge of the field of psychedelic research. Bryce laid much of the marketing groundwork for our brand, and in doing so advanced public education about psychedelics immeasurably.
A major highlight in Bryce’s career at MAPS occurred in an April 2016 episode of The Joe Rogan Experience, one of the top podcasts in the world. Joe Rogan and MAPS Founder and Executive Director Rick Doblin, Ph.D., publicly praised Bryce’s marketing work, leading to Joe Rogan stating, “Thumbs up, Bryce!” Watch the clip on Bryce’s Instagram.
Thank you, Bryce, for your 11 excellent years of dedication not only to MAPS, but to the entire field of psychedelic science. With deep gratitude, we wish you all the best in your future endeavors. We will miss your clever ideas and sharp insight!
Sending Gratitude To All MAPS Trial Applicants
Last month, MAPS PBC announced that the final participant in the second Phase 3 trial of MDMA-assisted therapy for PTSD (MAPP2) completed their final session in the clinical treatment protocol.
To the thousands of people who have applied to volunteer as a research participant in MAPS-sponsored clinical trials of MDMA-assisted therapy for PTSD, we are so thankful for your interest. MAPS recognizes the great need for an effective treatment for PTSD compared to currently available options. While we are unable to accept every applicant to our trials due to regulatory constraints, we are hopeful that one day the rigorous research we’re conducting will mean MDMA-assisted therapy for PTSD is widely available to all. We are grateful for your understanding, and we wish you healing and recovery.
First Speakers Announced for Psychedelic Science 2023
We’re thrilled to announce newly confirmed speakers and instructors for Psychedelic Science 2023! A wide array of speakers will be present, from researchers and practitioners to policy makers and entertainers, including:
- Tim Ferriss, Author, Investor, Founder at The Saisei Foundation
- Gül Dölen, M.D., Ph.D., Principal Investigator, Dölen Lab, Department Of Neuroscience at Johns Hopkins
- Paul Stamets, Mycologist
- Kassandra Frederique, Executive Director at Drug Policy Alliance
- Amanda Feilding, Executive Director at The Beckley Foundation
- Roland Griffiths, Ph.D., Founding Director, Center For Psychedelic And Consciousness Research, Departments Of Psychiatry And Neuroscience at Johns Hopkins
- Dr. Gabor Maté, Physician, Author, Public Speaker
Psychedelic Science 2023 takes place June 19-23, 2023, in Denver, Colorado, and is the largest psychedelic gathering in the world. Sign up for exclusive email updates to receive the latest news, or visit our website to explore the agenda or book a hotel to secure the best rates.
Psychedelic Fundamentals: Give the Gift of Learning
Psychedelic Fundamentals, the introductory course in the MAPS Digital Learning series, will guide you through the basics of psychedelics via a series of short, easy-to-follow lessons. The course takes just a few hours and provides you with an overview of the most interesting and important aspects of psychedelic history, science, clinical research, therapeutic uses, and harm reduction, backed by over 36 years of MAPS history as a leading institution for psychedelic education.
Use code HTCYM for 25% off registration for Psychedelic Fundamentals for yourself or your psychedelically curious friends!
In-depth courses on integration, peer support, and more are available for pre-order now. Order today for $80 in savings on each course…the discount only lasts until the courses are launched!
The Promising Science of Psychedelics CourseProduct on saleAvailable at a future date.
Integrating Psychedelic Experiences CourseProduct on saleAvailable at a future date.
Psychedelic Trip Planning CourseProduct on saleAvailable at a future date.
Psychedelic Peer Support CourseProduct on saleAvailable at a future date.
MAPS, MAPS PBC, and MAPS Europe Are Hiring
Check our careers page to apply for one of our many open job positions or refer a friend! All of our organizations — MAPS, MAPS Public Benefit Corporation, and MAPS Europe — are hiring for full-time roles from development to clinical science to regulatory compliance.
Merry Christmas, Happy Hanukkah, Happy Holidays, and Happy New Year to you and your loved ones! Thank you for reading the monthly MAPS Newsletter.
Policy & Advocacy
MAPS in the Media
- CNN Audio: What Promise Do Psychedelics Hold As Therapeutics? – Chasing Life with Dr. Sanjay Gupta
- Psychedelic Alpha: MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD
- Mashable: When Virtual Reality Meets Psychedelic Therapy
- The Denver Post: Colorado Legalized Psilocybin. Now What?
- Benzinga: EXCLUSIVE: MAPS To Host Major Psychedelics Event In 2023
Thank you to Dr. Bronner’s for their support of the MAPS Newsletter!